

**December 31, 2020**

Contents

Clinical Profile Documentation .....2

- Problems Tab .....2
  - New.....2
  - Updates .....7
- Lab Analytes & Panels .....8
  - Additions and Updates.....8

Medications..... 13

- Additions..... 13
- Updates ..... 14

Regimens..... 15

- Additions..... 15
- Updates ..... 15
- Renamed Regimens..... 16

Research..... 16

- Regimen Additions ..... 16
- Updates ..... 16

Billing ..... 17

- HCPCS Code Updates ..... 17
- CPT Code Additions ..... 18

# Clinical Profile Documentation

## Problems Tab

### New

The following items are available for documentation in **Problems** and appear on the **Charge Capture Report (CCR)**. *Additional ICD10 codes may display to present the surrounding nodes.*

Problem	ICD10 Code Choice(s)*
Backache (finding)	M54.9 - Dorsalgia, unspecified
Bleeding (finding)	R58 - Hemorrhage, not elsewhere classified
Breast lump	N63 Unspecified lump in breast N63.10 Unspecified lump in the right breast, unspecified quadrant N63.11 Unspecified lump in the right breast, upper outer quadrant N63.12 Unspecified lump in the right breast, upper inner quadrant N63.13 Unspecified lump in the right breast, lower outer quadrant N63.14 Unspecified lump in the right breast, lower inner quadrant N63.15 Unspecified lump in the right breast, overlapping quadrants N63.20 Unspecified lump in the left breast, unspecified quadrant N63.21 Unspecified lump in the left breast, upper outer quadrant N63.22 Unspecified lump in the left breast, upper inner quadrant N63.23 Unspecified lump in the left breast, lower outer quadrant N63.24 Unspecified lump in the left breast, lower inner quadrant N63.25 Unspecified lump in the left breast, overlapping quadrants N63.31 Unspecified lump in axillary tail of the right breast N63.32 Unspecified lump in axillary tail of the left breast N63.41 Unspecified lump in right breast, subareolar N63.42 Unspecified lump in left breast, subareolar
Bone pain (finding)	M85.80 - Other specified disorders of bone density and structure, unspecified site
Chest pain	R07.81 Pleurodynia R07.82 Intercostal pain R07.89 Other chest pain R07.9 Chest pain, unspecified
Chronic pain syndrome (disorder)	G89.4 - Chronic pain syndrome
Disorder of bone and articular cartilage (disorder)	M24.10 - Other articular cartilage disorders, unspecified site M89.9 - Disorder of bone, unspecified
Disorder of endocrine system (disorder)	E34.9 - Endocrine disorder, unspecified

Problem	ICD10 Code Choice(s)*
Disorder of lung (disorder)	J98.4 - Other disorders of lung
Headache	G44.321 Chronic post-traumatic headache, intractable R51.0 Headache with orthostatic component, not elsewhere classified R51.9 Headache, unspecified
Hyperbilirubinemia (disorder)	E80.6 - Other disorders of bilirubin metabolism
Imaging result abnormal (finding)	R93.89 - Abnormal findings on diagnostic imaging of other specified body structures
Lesion of liver (finding)	K76.89 - Other specified diseases of liver
Liver cell carcinoma (disorder)	C22.0 - Liver cell carcinoma
Mass of axilla (finding)	R22.9 - Localized swelling, mass and lump, unspecified
Mass of neck (finding)	R22.1 - Localized swelling, mass and lump, neck
Mass of pancreas (finding)	K86.9 - Disease of pancreas, unspecified
Methylenetetrahydrofolate reductase deficiency	E72.12 - Methylenetetrahydrofolate reductase deficiency
Neoplasm of meninges (disorder)	C70.0 - Malignant neoplasm of cerebral meninges C70.1 - Malignant neoplasm of spinal meninges C70.9 - Malignant neoplasm of meninges, unspecified C72.0 - Malignant neoplasm of spinal cord D32.0 - Benign neoplasm of cerebral meninges D32.1 - Benign neoplasm of spinal meninges D32.9 - Benign neoplasm of meninges, unspecified D33.4 - Benign neoplasm of spinal cord D42.0 - Neoplasm of uncertain behavior of cerebral meninges D42.1 - Neoplasm of uncertain behavior of spinal meninges D42.9 - Neoplasm of uncertain behavior of meninges, unspecified
Pain in axilla (finding)	M79.621 - Pain in right upper arm M79.622 - Pain in left upper arm M79.629 - Pain in unspecified upper arm
Palpitations (finding)	R00.2 - Palpitations
Pernicious anemia (disorder)	D51.0 - Vitamin B12 deficiency anemia due to intrinsic factor deficiency

Primary malignant neoplasm of breast (disorder)	<p>C50.011 - Malignant neoplasm of nipple and areola, right female breast</p> <p>C50.012 - Malignant neoplasm of nipple and areola, left female breast</p> <p>C50.019 - Malignant neoplasm of nipple and areola, unspecified female breast</p> <p>C50.111 - Malignant neoplasm of central portion of right female breast</p> <p>C50.112 - Malignant neoplasm of central portion of left female breast</p> <p>C50.119 - Malignant neoplasm of central portion of unspecified female breast</p> <p>C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast</p> <p>C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast</p> <p>C50.219 - Malignant neoplasm of upper-inner quadrant of unspecified female breast</p> <p>C50.311 - Malignant neoplasm of lower-inner quadrant of right female breast</p> <p>C50.312 - Malignant neoplasm of lower-inner quadrant of left female breast</p> <p>C50.319 - Malignant neoplasm of lower-inner quadrant of unspecified female breast</p> <p>C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast</p> <p>C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast</p> <p>C50.419 - Malignant neoplasm of upper-outer quadrant of unspecified female breast</p> <p>C50.511 Malignant neoplasm of lower-outer quadrant of right female breast</p> <p>C50.512 Malignant neoplasm of lower-outer quadrant of left female breast</p> <p>C50.519 Malignant neoplasm of lower-outer quadrant of unspecified female breast</p> <p>C50.611 Malignant neoplasm of axillary tail of right female breast</p> <p>C50.612 Malignant neoplasm of axillary tail of left female breast</p> <p>C50.619 Malignant neoplasm of axillary tail of unspecified female breast</p> <p>C50.811 Malignant neoplasm of overlapping sites of right female breast</p> <p>C50.812 Malignant neoplasm of overlapping sites of left female breast</p> <p>C50.819 Malignant neoplasm of overlapping sites of unspecified female breast</p> <p>C50.911 Malignant neoplasm of unspecified site of right female breast</p> <p>C50.912 Malignant neoplasm of unspecified site of left female breast</p> <p>C50.919 Malignant neoplasm of unspecified site of unspecified female breast</p> <p>C50.021 Malignant neoplasm of nipple and areola, right male breast</p> <p>C50.022 Malignant neoplasm of nipple and areola, left male breast</p>
---	--

Problem	ICD10 Code Choice(s)*
	breast C50.029 Malignant neoplasm of nipple and areola, unspecified male breast C50.121 Malignant neoplasm of central portion of right male breast C50.122 Malignant neoplasm of central portion of left male breast C50.129 Malignant neoplasm of central portion of unspecified male breast C50.221 Malignant neoplasm of upper-inner quadrant of right male breast C50.222 Malignant neoplasm of upper-inner quadrant of left male breast C50.229 Malignant neoplasm of upper-inner quadrant of unspecified male breast C50.321 Malignant neoplasm of lower-inner quadrant of right male breast C50.322 Malignant neoplasm of lower-inner quadrant of left male breast C50.329 Malignant neoplasm of lower-inner quadrant of unspecified male breast C50.421 Malignant neoplasm of upper-outer quadrant of right male breast C50.422 Malignant neoplasm of upper-outer quadrant of left male breast C50.429 Malignant neoplasm of upper-outer quadrant of unspecified male breast C50.521 Malignant neoplasm of lower-outer quadrant of right male breast C50.522 Malignant neoplasm of lower-outer quadrant of left male breast C50.529 Malignant neoplasm of lower-outer quadrant of unspecified male breast C50.621 Malignant neoplasm of axillary tail of right male breast C50.622 Malignant neoplasm of axillary tail of left male breast C50.629 Malignant neoplasm of axillary tail of unspecified male breast C50.821 Malignant neoplasm of overlapping sites of right male breast C50.822 Malignant neoplasm of overlapping sites of left male breast C50.829 Malignant neoplasm of overlapping sites of unspecified male breast C50.921 Malignant neoplasm of unspecified site of right male breast C50.922 Malignant neoplasm of unspecified site of left male breast C50.929 Malignant neoplasm of unspecified site of unspecified male breast

Problem	ICD10 Code Choice(s)*
Primary malignant neoplasm of male breast (disorder)	C50.021 Malignant neoplasm of nipple and areola, right male breast C50.022 Malignant neoplasm of nipple and areola, left male breast C50.029 Malignant neoplasm of nipple and areola, unspecified male breast C50.121 Malignant neoplasm of central portion of right male breast C50.122 Malignant neoplasm of central portion of left male breast C50.129 Malignant neoplasm of central portion of unspecified male breast C50.221 Malignant neoplasm of upper-inner quadrant of right male breast C50.222 Malignant neoplasm of upper-inner quadrant of left male breast C50.229 Malignant neoplasm of upper-inner quadrant of unspecified male breast C50.321 Malignant neoplasm of lower-inner quadrant of right male breast C50.322 Malignant neoplasm of lower-inner quadrant of left male breast C50.329 Malignant neoplasm of lower-inner quadrant of unspecified male breast C50.421 Malignant neoplasm of upper-outer quadrant of right male breast C50.422 Malignant neoplasm of upper-outer quadrant of left male breast C50.429 Malignant neoplasm of upper-outer quadrant of unspecified male breast C50.521 Malignant neoplasm of lower-outer quadrant of right male breast C50.522 Malignant neoplasm of lower-outer quadrant of left male breast C50.529 Malignant neoplasm of lower-outer quadrant of unspecified male breast C50.621 Malignant neoplasm of axillary tail of right male breast C50.622 Malignant neoplasm of axillary tail of left male breast C50.629 Malignant neoplasm of axillary tail of unspecified male breast C50.821 Malignant neoplasm of overlapping sites of right male breast C50.822 Malignant neoplasm of overlapping sites of left male breast C50.829 Malignant neoplasm of overlapping sites of unspecified male breast C50.921 Malignant neoplasm of unspecified site of right male breast C50.922 Malignant neoplasm of unspecified site of left male breast C50.929 Malignant neoplasm of unspecified site of unspecified male breast
Productive cough (finding)	R05 - Cough

Problem	ICD10 Code Choice(s)*
Pruritic disorder (disorder)	L29.0 - Pruritus ani L29.2 - Pruritus vulvae L29.3 - Anogenital pruritus, unspecified L29.8 - Other pruritus L29.9 - Pruritus, unspecified
Pseudoangiomatous stromal hyperplasia of breast (disorder)	N62 - Hypertrophy of breast
Right upper quadrant pain (finding)	R10.11 - Right upper quadrant pain
Scalding pain on urination (finding)	R30.9 - Painful micturition, unspecified
Sciatica (disorder)	M54.30 - Sciatica, unspecified side M54.31 - Sciatica, right side M54.32 - Sciatica, left side
Screening mammography (procedure)	Z12.31 - Encounter for screening mammogram for malignant neoplasm of breast
Seasonal allergic rhinitis (disorder)	J30.0 - Vasomotor rhinitis J30.1 - Allergic rhinitis due to pollen J30.2 - Other seasonal allergic rhinitis J30.5 - Allergic rhinitis due to food J30.81 - Allergic rhinitis due to animal (cat) (dog) hair and dander J30.89 - Other allergic rhinitis J30.9 - Allergic rhinitis, unspecified
Serum creatinine raised (finding)	R79.89 - Other specified abnormal findings of blood chemistry
Swelling of limb (finding)	M79.81 - Nontraumatic hematoma of soft tissue M79.89 - Other specified soft tissue disorders
Ultrasound scan abnormal (finding)	R92.8 Other abnormal and inconclusive findings on diagnostic imaging of breast
Urgent desire to urinate (finding)	R39.15 - Urgency of urination

## Updates

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

The following **Locations** are no longer available for charting:

- Renal Cell Cancer (NOTE: these locations will be available for charting on problems related to the Renal pelvis and ureter in the January Content release)
  - Bilateral renal pelvis
  - Bilateral ureters
  - Left renal pelvis
  - Left ureter
  - Right renal pelvis
  - Right ureter
  - Unspecified renal pelvis
  - Unspecified ureter
- Lung Cancer, Non-Small Cell (NSCLC)
  - Trachea
  - Cancers arising in the trachea are now in the solid tumor problem group

# Labs, Diagnostic Imaging and Other services

## Lab Analytes & Panels

### Additions and Updates

- 13q-/13 - 1R1G total counts
- 13q-/13 - 2R2G total counts
- 13q-/13 - nuclei analyzed
- 13q-/13 - result
- 1p32/1q21 - >=2R1G total counts
- 1p32/1q21 - >3R>=2G total counts
- 1p32/1q21 - 2R2G total counts
- 1p32/1q21 - 3R2G total counts
- 1p32/1q21 - nuclei analyzed
- 1p32/1q21 - result
- 5 hydroxyindolacetic acid panel, plasma
- 5-HIAA, plasma
- A/G ratio
- ACVR1B mutation analysis
- ACVR1B mutation analysis - mutation(s) detected
- ADMA, ng/mL
- ADMA/SDMA panel
- Advanced lipid panel with inflammation, Cardio IQ(R)
- AKT1 mutation analysis
- AKT1 mutation analysis - mutations(s)
- Albumin, SPE, g/dL
- Almond (F20), IgE
- Almond (F20), IgE class
- Alpha-1 globulin
- Alpha-2 globulin
- Antipsychotic drug screen panel, urine
- Antipsychotic screen, urine, qual
- Apolipoprotein B
- ARID1A mutation analysis
- ARID1A mutation analysis - ARID1A mutation analysis
- ARID1A mutation analysis - mutation(s)
- ARID1A mutation analysis - mutations(s)
- ASXL1 mutation analysis
- ASXL1 mutation analysis - mutation(s) detected
- ATM mutation analysis - ATM mutation analysis
- ATM mutation analysis - mutation(s)
- ATR mutation analysis
- ATR mutation analysis - mutation(s)
- ATRX mutation analysis - ATRX mutation analysis
- ATRX mutation analysis - mutation(s)
- Babesia microti PCR, qual
- Babesia PCR panel
- Insulin, free, uU/mL
- Insulin, total, serum
- Insulin, total, serum, uU/mL
- JAK2 Exon 12-14 mutation analysis - JAK2 EXON 12-14 mutation
- JAK2 Exon 12-14 mutation analysis - mutation(s)
- JAK2 V617F mutation analysis - qualitative - mutation(s)
- JAK2 V617F mutation analysis, qual
- KIT (c-KIT) mutation analysis - c-KIT Exon 11
- KIT (c-KIT) mutation analysis - c-KIT Exon 17
- KIT (c-KIT) mutation analysis - c-KIT Exon 8
- KIT (c-KIT) mutation analysis - c-KIT Exon 9
- KIT (c-KIT) mutation analysis - KIT (c-Kit) mutation
- KRAS mutation analysis
- KRAS mutation analysis - KRAS mutation
- KRAS mutation analysis - mutation(s)
- KRAS mutation analysis, mutation(s)
- Lab MG clinical recommendations
- Lab MG clinical significance
- Lab MG FDA statement
- Lab MG genetic significance
- Lab MG methodology
- Lab MG references
- Lab MG result summary
- Lab MG SS result
- LDL pattern
- LDL peak size
- LDL, cholesterol
- LDL, medium
- LDL-P
- LDL-P, small
- Lipoprotein A, nmol/L
- LP PLA2 activity
- Manganese panel, plasma
- Manganese, plasma, ug/L
- MEN1 mutation analysis
- MEN1 mutation analysis - mutation(s) detected
- Mesoridazine, urine, qual
- MET (c-MET) mutation analysis
- MET (c-MET) mutation analysis - mutation(s)
- MET (c-MET) mutation analysis - mutations(s)
- MET FISH
- MET FISH - MET FISH

- BAP1 mutation analysis - BAP1 mutation analysis
- BAP1 mutation analysis - mutation(s)
- BARD1 mutation analysis
- BARD1 mutation analysis - BARD1 mutation analysis
- BARD1 mutation analysis - mutation(s) detected
- BCOR mutation analysis - BCOR mutation analysis
- BCOR mutation analysis - mutation(s)
- Beta globulin
- BRAF full gene sequencing panel
- BRAF mutation analysis - BRAF mutation
- BRAF mutation analysis - mutation(s)
- BRAF mutation analysis mutation(s)
- BRAF mutation analysis, mutation(s)
- BRCA1 mutation analysis
- BRCA1 mutation analysis - mutation(s)
- BRCA2 mutation analysis
- BRCA2 mutation analysis - mutation(s)
- BRIP1 mutation analysis - BRIP1 mutation analysis
- BRIP1 mutation analysis - mutation(s) detected
- Cashew nut (F202), IgE
- Cashew nut (F202), IgE class
- CBC/BM Differential (CBC) Basophils
- CBC/BM Differential (CBC) comments
- CBC/BM Differential (CBC) date performed
- CBC/BM Differential (CBC) Eosinophils
- CBC/BM Differential (CBC) Hct
- CBC/BM Differential (CBC) HGB
- CBC/BM Differential (CBC) Lymphocytes
- CBC/BM Differential (CBC) MCH
- CBC/BM Differential (CBC) MCHC
- CBC/BM Differential (CBC) MCV
- CBC/BM Differential (CBC) monocytes
- CBC/BM Differential (CBC) Neutrophils
- CBC/BM Differential (CBC) performed at
- CBC/BM Differential (CBC) Plts
- CBC/BM Differential (CBC) RBC
- CBC/BM Differential (CBC) RDW
- CBC/BM Differential (CBC) WBC
- CCND1/IgH t(11;14) - 1R1G1F total counts
- CCND1/IgH t(11;14) - 1R1G2F total counts
- CCND1/IgH t(11;14) - 2R2G total counts
- CCND1/IgH t(11;14) - 2R3G total counts
- CCND1/IgH t(11;14) - result
- CCND1/IgH t(11;14) nuclei analyzed
- CDK12 mutation analysis
- CDK12 mutation analysis - mutation(s)
- CDK4 mutation analysis - CDK4 mutation analysis
- CDK4 mutation analysis - mutation(s) detected
- CDKN2A mutation analysis
- CDKN2A mutation analysis - mutation(s)
- CDKN2B mutation analysis
- MLH1 sequencing - MLH1 sequencing
- MLH1 sequencing result
- MLL mutation analysis
- MLL mutation analysis - mutation(s)
- Morphology analysis panel
- MP statement
- MRE11A mutation analysis
- MRE11A mutation analysis - mutation(s) detected
- MSH2 sequencing
- MSH2 sequencing result
- MSH6 sequencing - MSH6 sequencing
- MSH6 sequencing result
- MSI by NGS - note
- MSI by NGS microsatellite instability
- M-spike, serum
- NBN mutation analysis
- NBN mutation analysis - mutation(s)
- NBN mutation analysis - mutation(s) detected
- NeoTYPE AITL/Peripheral T-Cell Lymphoma comments
- NeoTYPE AITL/Peripheral T-Cell Lymphoma PDF
- NeoTYPE AML prognostic PDF
- NeoTYPE AML prognostic profile comments
- NeoTYPE Cervical tumor PDF
- NeoTYPE Cervical tumor profile comments
- NeoTYPE HRD+ PDF
- NeoTYPE HRD+ profile comments
- NeoTYPE Melanoma PDF
- NeoTYPE Melanoma profile comments
- NeoTYPE Pancreas tumor profile comments
- NeoTYPE Pancreas tumor profile PDF
- NeoTYPE(TM) AITL/Peripheral T-Cell Lymphoma profile
- NeoTYPE(TM) AML prognostic profile
- NeoTYPE(TM) Cervical tumor profile
- NeoTYPE(TM) GI predictive profile comments
- NeoTYPE(TM) GI predictive profile panel
- NeoTYPE(TM) HRD+ profile
- NeoTYPE(TM) Melanoma profile
- NeoTYPE(TM) other solid tumor profile comments
- NeoTYPE(TM) other solid tumor profile panel
- NeoType(TM) pancreas tumor profile
- New Coumadin dose
- NF1 mutation analysis
- NF1 mutation analysis - mutation(s)
- Non-HDL cholesterol
- NOTCH1 mutation analysis
- NOTCH1 mutation analysis - mutation(s) detected
- NPM1 mutation analysis
- NRAS mutation analysis - mutation(s)
- NRAS mutation analysis - NRAS mutation
- NRAS mutation analysis, mutation(s)
- NRAS mutation analysis, NRAS mutation

- CDKN2B mutation analysis - mutation(s)
- CEBPA mutation analysis - CEBPA mutation
- CEBPA mutation analysis - mutation(s)
- CEBPA mutation analysis - SNP rs34529039
- CHEK1 mutation analysis
- CHEK1 mutation analysis - mutation(s) detected
- CHEK2 mutation analysis
- CHEK2 mutation analysis - mutation(s) detected
- Chlorpromazine, urine, qual
- Cholesterol, total
- Cholesterol/HDL ratio
- Chromogranin A
- Chromogranin A Re-Baseline panel
- Chromogranin A, intact/fragments
- Chromogranin A, serum, ng/mL
- Clinical exome panel
- Clozapine, urine, qual
- COMPASS bone marrow evaluation panel
- COMPASS bone marrow evaluation, comments
- COMPASS bone marrow evaluation, cytogenetics
- COMPASS bone marrow evaluation, flow cytometry
- COMPASS bone marrow evaluation, morphology
- COVID-19 Ab, IgG, AU/mL
- COVID-19 Ab, IgM, AU/mL
- COVID-19 screen panel
- COVID-19 screen, qual
- Creatinine, urine, per 24H
- Creatinine, urine, per volume
- CSF3R mutation analysis
- CSF3R mutation analysis - mutation(s)
- CTNNB1 mutation analysis
- CTNNB1 mutation analysis - mutation(s)
- Current Coumadin dose
- DNase B antibody titer panel
- DNase B antibody, unit/mL
- DNMT3A mutation analysis
- DNMT3A mutation analysis - DNMT3A mutation
- DNMT3A mutation analysis - mutation(s)
- EGFR mutation analysis by Sanger - EGFR Exon 18
- Onkosight advanced chronic lymphoid neoplasm NGS interpretation summary
- Onkosight advanced chronic lymphoid neoplasm NGS methods
- Onkosight advanced chronic lymphoid neoplasm NGS panel
- Onkosight advanced chronic lymphoid neoplasm NGS PDF
- Onkosight advanced chronic lymphoid neoplasm NGS references
- Onkosight advanced chronic lymphoid neoplasm NGS report
- Onkosight advanced chronic lymphoid neoplasm NGS report footer
- p53 (17p13.1)/ NF1 (17q11) - 1R1G total counts
- p53 (17p13.1)/ NF1 (17q11) - 1R2G total counts
- p53 (17p13.1)/ NF1 (17q11) - 2R2G total counts
- p53 (17p13.1)/ NF1 (17q11) - nuclei analyzed
- p53 (17p13.1)/ NF1 (17q11) - result
- PALB2 mutation analysis
- PALB2 mutation analysis - mutation(s)
- Pancreatic elastase, fecal panel
- Pancreatic elastase, fecal, ug Elast/g
- Pan-TRK
- Pan-TRK - Marker Result
- Pan-TRK - Pan-TRK
- Pan-TRK marker result
- PBRM1 mutation analysis
- PBRM1 mutation analysis - mutation(s)
- PDGFRa mutation analysis - mutation(s)
- PDGFRa mutation analysis - PDGFRa mutation(s)
- PD-L1 (28-8)
- PD-L1 (28-8) panel
- PD-L1 22C3 FDA (Keytruda) for Cervical combined positive score
- PD-L1 22C3 FDA (Keytruda) for Cervical result
- PD-L1 22C3 FDA (KEYTRUDA) for Gastric/GEA - combined positive score
- PD-L1 22C3 FDA (KEYTRUDA) for Gastric/GEA - PD-L1 22C3 FDA (KEYTRUDA) for Gastric/GEA
- PD-L1 22C3 FDA (Keytruda) for Gastric/GEA combined positive score
- PD-L1 22C3 FDA (KEYTRUDA) for Gastric/GEA result
- PD-L1 22C3 FDA (KEYTRUDA) for Gastric/GEA, PD-L1 22C3 FDA (KEYTRUDA) for Gastric/GEA
- PD-L1 28-8 FDA (Opdivo) - Intensity
- PD-L1 28-8 FDA (Opdivo) - PD-L1 28-8 FDA (Opdivo)
- PD-L1 28-8 FDA (OPDIVO) tumor stained
- PD-L1 28-8 FDA (Opdivo) tumor type
- Perphenazine, urine, qual
- PHF6 mutation analysis - mutation(s)

- EGFR mutation analysis by Sanger - EGFR Exon 19
- EGFR mutation analysis by Sanger - EGFR Exon 20 other mutations
- EGFR mutation analysis by Sanger - EGFR Exon 20 T790M
- EGFR mutation analysis by Sanger - EGFR Exon 21
- EGFR mutation analysis by Sanger - overall result
- ER/PR/Her2/Neu result
- ER/PR/Her2/Neu status panel
- ERBB2 mutation analysis
- ERBB2 mutation analysis - mutation(s)
- ERBB4 mutation analysis
- ERBB4 mutation analysis - mutation(s)
- ETV6 mutation analysis
- ETV6 mutation analysis - mutation(s)
- EZH2 mutation analysis
- EZH2 mutation analysis - mutation(s) detected
- Factor XIII antigen
- Factor XIII antigen panel
- FANCA mutation analysis
- FANCA mutation analysis - mutation(s) detected
- FANCC mutation analysis
- FANCC mutation analysis - mutation(s) detected
- FANCD2 mutation analysis
- FANCD2 mutation analysis - mutation(s) detected
- FANCE mutation analysis
- FANCE mutation analysis - mutation(s) detected
- FANCF mutation analysis
- FANCF mutation analysis - mutation(s) detected
- FANCG mutation analysis
- FANCG mutation analysis - mutation(s) detected
- FANCL mutation analysis
- FANCL mutation analysis - mutation(s) detected
- FBXW7 mutation analysis
- FBXW7 mutation analysis - mutation(s)
- FGFR1 mutation analysis
- FGFR1 mutation analysis - mutation(s)
- FGFR2 mutation analysis
- FGFR2 mutation analysis - mutation(s)
- FGFR3 mutation analysis
- FGFR3 mutation analysis - mutation(s)
- FGFR3/IgH t(4;14) - 1R1G1F total counts
- FGFR3/IgH t(4;14) - 1R1G2F total counts
- FGFR3/IgH t(4;14) - 2R2G total counts
- FGFR3/IgH t(4;14) - 2R3G total counts
- FGFR3/IgH t(4;14) - nuclei analyzed
- FGFR3/IgH t(4;14) - result
- FGFR4 mutation analysis
- PHF6 mutation analysis - PHF6 mutation analysis
- PIK3CA LDT mutation analysis by sequencing
- PIK3CA LDT mutation analysis by sequencing - PIK3CA Exon 1
- PIK3CA LDT mutation analysis by sequencing - PIK3CA Exon 20
- PIK3CA LDT mutation analysis by sequencing - PIK3CA Exon 9
- Plasma cell myeloma prognostic panel, bone marrow
- Plasma cell myeloma prognostic panel, comments
- PML mutation analysis - mutation(s) detected
- PML mutation analysis - PML mutation analysis
- PMS2 sequencing - PMS2 sequencing
- PMS2 sequencing result
- Prochlorperazine, urine, qual
- Promazine, urine, qual
- Promethazine, urine, qual
- Protein electrophoresis, serum with reflex to IFE, serum panel
- Protein, urine Bence-Jones, %
- Prothrombin antibody IgG panel
- Prothrombin antibody, IgG, G units
- PT, point of care
- PT/INR POC panel
- PTEN FISH
- PTEN FISH - PTEN FISH
- PTEN FISH note
- PTEN mutation analysis - mutation(s)
- PTEN mutation analysis - mutation(s) detected
- PTEN mutation analysis - PTEN mutation analysis
- PTPN11 mutation analysis - mutation(s)
- PTPN11 mutation analysis - mutation(s) detected
- PTPN11 mutation analysis - PTPN11 mutation analysis
- RAD50 mutation analysis
- RAD50 mutation analysis - mutation(s) detected
- RAD51 mutation analysis
- RAD51 mutation analysis - mutation(s) detected
- RAD51B mutation analysis
- RAD51B mutation analysis - mutation(s)
- RAD51C mutation analysis
- RAD51C mutation analysis - mutation(s)
- RAD51D mutation analysis
- RAD51D mutation analysis - mutation(s) detected
- RAD54L mutation analysis
- RAD54L mutation analysis - mutation(s) detected
- RHOA mutation analysis - mutation(s)
- RHOA mutation analysis - RHOA mutation analysis
- RNF43 mutation analysis
- RNF43 mutation analysis - mutation(s) detected
- RUNX1 mutation analysis - mutation(s) detected

- FGFR4 mutation analysis - mutation(s) detected
- FLT3 mutation analysis - FLT3 mutation
- FLT3 mutation analysis - FLT3-ITD insertion size (bp)
- Fluphenazine, urine, qual
- Gamma globulin
- Genomic LOH
- Globulin, g/L
- GNA11 mutation analysis
- GNA11 mutation analysis - mutation(s)
- GNAQ mutation analysis
- GNAQ mutation analysis - mutation(s)
- GNAS mutation analysis
- GNAS mutation analysis - mutation(s)
- Haloperidol, urine, qual
- Hazelnut (F17), IgE
- Hazelnut (F17), IgE class
- HDL cholesterol
- HDL, large
- HER2 Non-Breast FISH - Average CEN17 signals
- HER2 Non-Breast FISH - Average HER2 signals
- HER2 Non-Breast FISH - HER2 Non-Breast FISH
- HER2 Non-Breast FISH - HER2/CEN17 ratio
- HER2 Non-Breast FISH average CEN17 signals
- HER2 Non-Breast FISH average HER2 signals
- HER2 Non-Breast FISH HER2/CEN17 Ratio
- High-sensitivity Troponin I panel
- HLA-DR4
- HLA-DR4 flow cytometry panel
- HRAS mutation analysis - HRAS mutation
- HRAS mutation analysis - mutation(s)
- HRAS mutation analysis, mutation(s)
- HS CRP
- HS Troponin I, pg/mL
- IDH1 mutation analysis
- IDH1 mutation analysis - mutation(s)
- IDH1/IDH2 mutation analysis - IDH1 mutation
- IDH1/IDH2 mutation analysis - IDH1/IDH2 mutation
- IDH1/IDH2 mutation analysis - IDH2 mutation
- IDH2 mutation analysis
- IDH2 mutation analysis - mutation(s) detected
- IFE interpretation
- IgA, quant
- IgG, quant
- IgH/MAF t(14;16) - 1R1G1F total counts
- IgH/MAF t(14;16) - 1R1G2F total counts
- IgH/MAF t(14;16) - 2R2G total counts
- IgH/MAF t(14;16) - 2R3G total counts
- IgH/MAF t(14;16) - nuclei analyzed
- RUNX1 mutation analysis - RUNX1 mutation analysis
- Salmon (F41), IgE
- Salmon (F41), IgE class
- SARS-CoV-2 IgG/IgM Ab panel
- SARS-CoV-2 IgG/IgM, Ab
- SDMA, ng/mL
- SETBP1 mutation analysis - mutation(s)
- SETBP1 mutation analysis - SETBP1 mutation
- Sjogren's antibody (SSA/RO), qual
- Sjogren's antibody (SSB/LA), qual
- SMAD4 mutation analysis
- SMAD4 mutation analysis - mutation(s)
- SMAD4 mutation analysis - SMAD4 mutation analysis
- SMO mutation analysis
- SMO mutation analysis - mutation(s)
- SRC mutation analysis
- SRC mutation analysis - mutation(s)
- SSA/SSB panel
- STAG2 mutation analysis - mutation(s)
- STAG2 mutation analysis - STAG2 mutation analysis
- STK11 mutation analysis
- STK11 mutation analysis - mutation(s)
- STK11 mutation analysis - STK11 mutation analysis
- Target INR
- T-cell receptor (TCR) gamma gene rearrangement PCR
- T-cell receptor (TCR) gamma gene rearrangement PCR panel
- TERT gene promoter mutation analysis by NGS
- TERT gene promoter mutation analysis by NGS - mutation(s)
- TERT gene promoter mutation analysis by NGS mutation(s)
- TET2 mutation analysis
- TET2 mutation analysis - mutation(s) detected
- TET2 mutation analysis - TET2 mutation analysis
- TGFBR2 mutation analysis
- TGFBR2 mutation analysis - mutation(s) detected
- Thioridazine, urine, qual
- Total protein
- TP53 mutation analysis
- TP53 mutation analysis - TP53 Exon 4
- TP53 mutation analysis - TP53 Exon 5
- TP53 mutation analysis - TP53 Exon 6
- TP53 mutation analysis - TP53 Exon 7
- TP53 mutation analysis - TP53 Exon 8
- TP53 mutation analysis - TP53 Exon 9
- Trifluoperazine, urine, qual
- Triglycerides
- Tuna (F40), IgE
- Tuna (F40), IgE class
- UGT1A1 gene (TA repeat) additional information

- IgH/MAF t(14;16) - result
- IgH/MAFB t(14;20) - 1R1G1F total counts
- IgH/MAFB t(14;20) - 1R1G2F total counts
- IgH/MAFB t(14;20) - 2R2G total counts
- IgH/MAFB t(14;20) - 2R3G total counts
- IgH/MAFB t(14;20) - 3R2G total counts
- IgH/MAFB t(14;20) - nuclei analyzed
- IgH/MAFB t(14;20) - result
- IgM, quant
- Immunofixation (IFE) urine panel
- Immunofixation reflex
- Immunofixation, urine interpretation
- INR, point of care
- Insulin free and total panel
- Insulin, free
- UGT1A1 gene (TA repeat) director review
- UGT1A1 gene (TA repeat) result
- Vanillylmandelic acid (VMA) timed urine panel
- Vanillylmandelic acid interpretation
- Vanillylmandelic acid, per 24H
- Vanillylmandelic acid, per volume
- Vanillylmandelic acid, ratio to CRT
- VHL mutation analysis
- VHL mutation analysis - mutation(s)
- Von Willebrand activity, pre
- Von Willebrand activity, pre, %
- WT1 mutation analysis
- WT1 mutation analysis - mutation(s)
- WT1 mutation analysis - SNP rs16754

## Medications

### Additions

- ASTX727 invest Oral
- ATI-0918 invest IV
- AZD2014 invest Oral
- Bamlanivimab (EUA) IV
- BEZ235 invest Oral
- Casirivimab (REGN10933) IV
- CG-806 G2 Formulation invest Oral
- Dendritic cell vaccine loaded with killed allogeneic melanoma cells invest Subcutaneous
- Dostarlimab or pembrolizumab invest IV
- EP-100 invest IV
- G-202 invest IV
- GX15-070MS invest IV
- H3B-6545 invest Oral
- Imdevimab (REGN10987) IV
- JNJ-64619178 invest Oral
- LCL161 invest Oral
- MCLA-128 invest IV
- Naxitamab-ggqk IV
- Niraparib/abiraterone acetate Oral
- Nuesch Mouthwash Oral Solution
- Nuesch Radiation Ointment Topical
- Nuesch Special Skin Topical Gel
- Pegfilgrastim-apgf Subcutaneous
- PHA-848125AC invest Oral
- Pimasertib invest Oral
- RX-0201 invest IV
- SAR439859 (amcenestrant) invest Oral
- STI571 invest or placebo Oral
- StrataXRT Topical Gel
- Venetoclax invest Oral

- ZN-c5 invest Oral

## Updates

- Regorafenib invest Oral – Form: 30 mg Tablet is now available.
- Letrozole Oral – Form: 2.5 mg over-encapsulated Tablet is now available.
- Max Dose Updates

Drug Name	Removed Maximum Single Dose	New Maximum Single Dose	Rounding Rule
Bleomycin IV	20 units/m2		
Brentuximab Vedotin IV	1.8 mg/kg		
Cetuximab IV	500 mg/m2		
Cyclophosphamide IV	2500 mg	3125 mg	
Cytarabine (PF) Intrathecal	3000 mg/m2; 7500 mg (intravenous/intravenously)	100 mg intrathecally	
Cytarabine IV	1400 mg/m2 via continuous infusion; 3000 mg/m2 intravenous/intravenously		
Daunorubicin IV			None
Docetaxel IV	100 mg/m2		
Elotuzumab IV	20 mg/kg		
Epirubicin IV			None
Etoposide Oral	125 mg	250 mg	
Filgrastim-aafi IV	10 mcg/kg		None
Filgrastim-sndz IV	10 mcg/kg		None
Filgrastim-aafi Subcutaneous	10 mcg/kg		None
Filgrastim-sndz Subcutaneous	10 mcg/kg		none
Infliximab-axxq IV	10 mg/kg		10 mg
Infliximab-dyyb IV	10 mg/kg		
Irinotecan IV	875 mg	880 mg	
Irinotecan Liposomal IV		175 mg intravenously	1 mg
Leucovorin IV	20 mg/m2 and 50 mg intramuscularly; 500 mg/m2 intravenous/intravenously		
Leucovorin IM	20 mg/m2 intramuscularly; 500 mg/m2 intravenously/intravenous		
Lurbinectedin IV	3.2 mg/m2		

Drug Name	Removed Maximum Single Dose	New Maximum Single Dose	Rounding Rule
Mercaptopurine Oral	75 mg/m <sup>2</sup> ; 175 mg	200 mg	
Mercaptopurine Oral Suspension			25 mg
Mercaptopurine Oral Suspension		200 mg	25 mg
Methotrexate Oral	20 mg/m <sup>2</sup>		
Mitoxantrone IV			None
Paclitaxel Intraperitoneal	60 mg/m <sup>2</sup>		
Tafasitamab-cxix IV	12 mg/kg		
Topotecan IV	4 mg/m <sup>2</sup>		
Trastuzumab-dttb IV		1200 mg	10 mg

## Regimens

### Additions

The following regimens are now available for ordering in the Regimen Library:

- Atezolizumab + Bevacizumab BIOSIMILAR Q21D
- Durvalumab Q28D (Flat Dose, Consolidation NSCLC)
- EMA/CO Q14D (D8 CO: Cyclophosphamide + Vincristine only)
- Pembrolizumab + Gemcitabine D1,8 + Carboplatin D1,8 Q21D
- Pembrolizumab (Q21D) + Abraxane (D1,8,15 Q21D) Q84D
- Pembrolizumab (Q21D) + Paclitaxel (D1,8,15 Q21D) Q84D
- Tamoxifen Q30D (Ovarian)

### Updates

NOTE: Paclitaxel containing regimens have been updated to include final diluent instructions.

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- All Problems
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- Fallopian Tube Cancer
- Gestational Trophoblastic Tumor
- Hepatocellular Carcinoma (HCC)
- Leukemia, Chronic Lymphocytic (CLL)

- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Ovarian and Primary Peritoneal Cancer
- Rectal Cancer
- Renal Cell Carcinoma (RCC)
- Thyroid Cancer (Parent)

## Renamed Regimens

Previous Name	New Name
Epoetin Alfa Q7D	Epoetin alfa Q7D
Lenvatinib Q30D (Thyroid Cancer)	Lenvatinib Q30D (Thyroid)
Regorafenib Dose Titration	Regorafenib Dose Titration D1-21 Q28D
Sorafenib	Sorafenib Q30D

## Research

### Regimen Additions

To support Data Migration, applicable clinical trial regimens for US Oncology Research have been migrated and modified for customers migrating from iKnowMed Generation 1 to iKnowMed Generation 2.

### Updates

The USOR Clinical Trials listed in the table below are updated:

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
				Other Changes
USOR 16238	X		X	
USOR 18103	X			The following regimen is now available for ordering: USOR 18103 Niraparib/Abiraterone FDC + Prednisone
USOR 18177	X	X	X	The following regimens are no longer available for ordering: USOR 18177 ASTX727 LD 10 Day Schedule USOR 18177 ASTX727 LD 7 Day Schedule Q28D
USOR 18194	X	X	X	Dose Escalation is complete; the following regimen is no longer available for ordering: USOR 18194 Part 1 Dose Escalation STRO-002 Q21D

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 18234	X	X	X	Dose Escalation is closed; the following regimens are no longer available for ordering: USOR 18234 AB928 (PO; Daily) + Pemetrexed + Carboplatin Q21D USOR 18234 AB928 (PO; Daily) + Pemetrexed Maintenance Therapy Q21D USOR 18234 AB928 (PO; Daily) + Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 18234 AB928 (PO; Daily) + Pembrolizumab + Pemetrexed Maintenance Therapy Q21D
USOR 18281	X		X	The following regimens are now available for ordering: USOR 18281 BA Sub-Study (G1 to G2) CG-806 (PO; BID) Q28D USOR 18281 BA Sub-Study (G2 to G1) CG-806 (PO; BID) Q28D
USOR 19081	X	X	X	
USOR 19160	X	X	X	The following regimen is now available for ordering: USOR 19160 Treatment Period Pembrolizumab or Placebo + Docetaxel + Carboplatin +/- Bevacizumab Q21D
USOR 19193	X	X		
USOR 20172	X			The following regimens are now available for ordering: USOR 20172 Cohort L Enfortumab Vedotin D1,8 Q21D (Neoadjuvant) USOR 20172 Cohort L Enfortumab Vedotin D1,8 Q21D (Adjuvant)
USOR 20250			X	
USOR 20258	X		X	
USOR 20283	X		X	
USOR 20284	X			
USOR 20996	X	X	X	

## Billing

### HCPCS Code Updates

Medication	HCPCS Code
Bamlanivimab (EUA) IV	Q0239 per 700 mg
Casirivimab (REGN10933) IV (1 of 2) (EUA)	Q0243 per 1200 mg
COVID-19 Vaccine, mRNA-1273 (Moderna) (PF) IM (Unapproved)	91301 per 0.5 mL
COVID-19 Vacc, mRNA, BNT162b2 (Pfizer) (PF) IM (Unapproved)	91300 per 0.3 mL
Dip,Per(a) Tet-HepB-Pol-Hib (PF) IM 15 unit-5 unit-10 mcg/0.5 mL	90697 per 0.5 mL

Medication	HCPSC Code
Imdevimab (REGN10987) IV (2 of 2) (EUA)	Q0243 per 1200 mg
Pegfilgrastim-apgf Subcutaneous	Q5122 per 0.5 mg

## CPT Code Additions

- Fluoroscopic guidance for central venous access device placement, replacement or removal is now available for charting and will capture CPT code 77001 (FLUORO CENTRAL VENOUS ACCESS DEV PLACEMENT).